Bristol Myers to cut over 500 jobs as part of restructuring
US pharma major Bristol Myers Squibb (NYSE: BMY) is set to lay off another 516 employees at its New Jersey, USA site, continuing a series of workforce reductions that have marked a sweeping restructuring campaign.
According to a state filing, the latest round of cuts will take place in stages from May this year through March 2026. The notification, posted under the state’s Worker Adjustment and Retraining Notification (WARN) system, lists 13 effective dates across that timeframe.
This follows multiple earlier job reductions at the same site, where the company had already let go of 67 employees in April, 223 more in June and August, and 195 toward the end of 2024.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze